Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MEDI4736 · 1 trial · 4 indications
Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment
ORR was defined as the percentage of participants having a complete response (CR) or partial response (PR) as determined by investigator assessment of radiographic disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
| Arm | Type | Description |
|---|---|---|
| MEDI4736 + INCB024360 | EXPERIMENTAL | MEDI4736 at selected dose levels every 2 weeks + INCB024360 25 mg BID as starting dose, followed by dose escalations until MTD or PAD is identified |
| Name | Type | Description |
|---|---|---|
| MEDI4736 | DRUG | MEDI4736 administered intravenously (IV) every two weeks (q2w) |
| INCB024360 | DRUG | INCB024360: Oral daily dosing |
Inclusion Criteria: * Male or female subjects, age 18 years or older * Histologically or cytologically confirmed diagnosis of selected locally advanced or metastatic solid tumors * Must have failed at least 1 prior treatment regimen for locally advanced or metastatic disease or be intolerant to tre...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
MEDI4736, also known as durvalumab, is an investigational drug being studied for the treatment of solid tumors, including head and neck cancer, lung cancer, and urothelial cancer. It is being evaluated in combination with epacadostat in patients with selected advanced solid tumors.
MEDI4736 is being developed by Incyte Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker symbol INCY. The drug is being studied in combination with epacadostat for the treatment of advanced solid tumors.
MEDI4736 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 study evaluating MEDI4736 in combination with epacadostat has been completed.
MEDI4736 was studied in a Phase 1 clinical trial with the identifier NCT02318277, titled 'A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)'. The trial enrolled 176 participants and has been completed.
Yes, MEDI4736 is also known as durvalumab. In clinical trials, it is referred to by both names, with the study title using 'Durvalumab (MEDI4736)' to identify the drug.